tbuckley/cabot-search huggingface dataset:
Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia.
Authors: M S Tallman, D Hakimian, C Zanzig, D K Hogan, A Rademaker, E Rose, D Variakojis
Journal: Journal of Clinical Oncology (1995)

PURPOSE Cladribine (2-CdA), a purine analog resistant to adenosine deaminase, has significant activity in a variety of lymphoproliferative diseases. This study was designed to determine the efficacy of 2-CdA in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). PATIENTS AND METHODS Twenty-six patients aged 40 to 88 years (median, 64) who either had relapsed after an initial response or were refractory to conventional chemotherapy with at least an alkylating agent were treated with 2-CdA 0.1 mg/kg/d by continuous intravenous infusion for either 5 or 7 days every 28 days for a maximum of six cycles. RESULTS No complete remissions (CRs) occurred. Eight of 26 patients (31%) achieved a partial remission (PR). The actuarial median time to progression (TTF) in responding patients is 16 months (range, 6 to 22). The actuarial median survival duration of the responding patients is 12 months (range, 8 to 28). Eight of 26 patients (31%) sustained early toxicity. Seven of these eight patients died before the first reevaluation of infection (n = 3), pericardial tamponade (n = 1), Stevens-Johnson syndrome (n = 1), and stroke (n = 2). No nausea, emesis, alopecia, or renal, hepatic, or cardiac toxicity was observed. CONCLUSION 2-CdA has activity in patients with relapsed or refractory CLL. However, patients who have received multiple prior regimens that included fludarabine are less likely to respond, and there can be significant morbidity. Treatment of patients with less prior therapy earlier in the natural history of the disease may lead to improved and more durable responses.
Abstract P035: Predictors of Diabetes Screening in an Ambulatory Clinical Population
Authors: Sukyung Chung, Eric C Wong, Kristen M Azar, Beinan Zhao, Diane Lauderdale, Latha Palaniappan
Journal: Circulation (2012)

Introduction Early screening for diabetes is the most cost effective way to prevent complications. Diabetes screening rates in a clinical population are unknown. There are well-known racial/ethnic differences in diabetes prevalence, with some Asian Americans racial/ethnic subgroups (e.g. Asian Indian and Filipino) having higher rates than Non Hispanic White (NHW) populations, and this may result in higher rates of diabetes screening for Asian Americans. Hypothesis We hypothesized that, after taking into account other risks factors suggested by national guidelines, Asian Americans may have higher preventive screening rates, given known higher risk for diabetes. Methods We used the electronic health records data from a large multi-specialty, mixed-payer, outpatient, group- practice organization in Northern California, to examine an observational prospective dataset during 1/1/2007-09/30/2010. Active primary care patients who were 35 years or older, not pregnant, identified as Asian (Asian Indian, Chinese, Filipino, Japanese, Korean, Vietnamese) or non-Hispanic white (NHW), and were free from diabetes at baseline were included (N=110,477). Screening was defined as fasting glucose, oral glucose tolerance test, or HgBA1C. Racial/ethnic differences in screening rates were initially examined with age-sex standardization. We then estimated a Cox proportional hazard model, which adjusted for diabetes clinical risk factors (including age, sex, BMI, high blood pressure, high LDL, low HDL), family history of diabetes, insurance coverage, and frequency of primary care visits. Results Standardized preventive screening rates were higher for all Asian racial/ethnic subgroups (ranging from 82.2%: Japanese to 88.7%: Filipino) than NHW (78.6%)( P&lt;0.05 ). The results were consistent in the fully adjusted Cox model where all the Asian racial/ethnic subgroups, except for Japanese (not significant), were more likely to be screened than NHWs (HR=Asian Indian: 1.29, Chinese: 1.20, Filipino: 1.22, Korean: 1.13, Vietnamese: 1.24; all P&lt;0.01 ). Most clinical risk factors were significant positive predictors of screening, including age, female, high blood pressure, high LDL, low HDL, and family history of diabetes(all P&lt;0.01 ). Conclusions Screening rates for diabetes in an insured, ambulatory care population is generally high (∼80%). Clinical risk factors and Asian race/ethnicity are predictors of appropriate diabetes screening.
Abstract 14641: Effect of Nicorandil on Clinical Outcomes in Patient With Acute Myocardial Infarction
Authors: Jin sup Park, Han Cheol Lee, Hye Yoon Jang, Jong Hyun Choi, Jin Hee Kim, Jin Hee Ahn, Hye Won Lee, Jung Hyun Choi, Junhyok Oh, Kwang Soo Cha, Taek Jong Hong, Mi-Jin Yang
Journal: Circulation (2013)

Nicorandil has cardiac protective effect in the ischemic myocardium, which is related to ischemic preconditioning, prevent vasospasm, myocardial necrosis, and improve coronary artery perfusion. We ...
Evaluation of distant spread in bevacizumab-treated versus control-treated patients with malignant gliomas: A matched-pair study.
Authors: M. Platten, N. Dörner, S. Hofer, N. Schäfer, D. Schemmer, M. Weller, M. Bendszus, W. Wick, A. Wick
Journal: Journal of Clinical Oncology (2010)

2064 Background: There is preclinical evidence that antiangiogenic therapies promote glioma cell invasiveness. Specifically, bevacizumab (BEV) may induce distant tumor spread in patients with glioblastoma. We have previously developed a tool to analyze recurrence patterns in a group-wise manner. We tested the hypothesis that BEV treatment of recurrent malignant glioma increases the frequency of distant tumor spread. Methods: Matched pairs of patients treated with or without BEV-containing regimens at recurrence were generated. Analysis was done on contrast-enhanced T1-weighted and on fluid-attenuated inversion recovery (FLAIR) magnetic resonance images (MRI). Distant spread was operationally defined as either of the following: a) center-of-mass movement > 50% of the pretreatment tumor diameter, b) > 2-fold increase of the pretreatment tumor diameter, c) new tumor satellites or d) involvement of the contralateral hemisphere. Forty pairs were determined to be sufficient to detect a 30% difference, which was regarded clinically meaningful with a power of 80%. Results: Forty-four matched pairs (age 47 [28-75] in the BEV and 52 [31-72] in the non-BEV group) were analyzed with a median of 2 (range 1-5) prior relapses and treatments, 20% distant recurrences with prior treatments and a median time to progression of 6.16 (BEV) and 4.9 (non-BEV) months. The progression-free survival rate at 6 months achieved with the treatment was 36% for BEV and 32% for non-BEV patients. Responses (complete or partial) according to the response assessment in Neurooncology (RANO) working group criteria were seen in 32% (BEV) and 7% (non-BEV). Distant recurrences were observed in 22% (10 of 44, BEV) and 18% (8 of 44, non-BEV) on T1 and in 25% (11 of 44, BEV) and 18% (8 of 44, non-BEV) on FLAIR sequences (p > 0.05, t-test). Conclusions: The proportion of distant recurrences is in line with previous observations but does not differ between BEV and non-BEV containing treatments arguing against a specific property of BEV-treatment to induce distant tumor growth or a gliomatosis-like phenotype at recurrence. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Merck, Merck Serono, Roche, Schering-Plough Merck, Merck Serono, Roche, Schering-Plough, Wyeth Lilly, Merck Serono, Schering-Plough
Patients’ decision-making process of participating in phase I oncology studies
Authors: M. Agrawal, C. Grady, D. Fairclough, E. Emanauel
Journal: Journal of Clinical Oncology (2005)

6014 Background: Phase I oncology trials are commonly challenged with claims that enrolled patients lack information necessary to make informed decisions and are vulnerable to being coerced into participating. This study assesses patients’ awareness of other options, the information they considered key to their decision, and the pressures they felt to participate. Methods: 142 cancer patients from 5 centers who enrolled in a phase I cancer trial, understood English, and were 18 or older were surveyed just after consenting. Results: Overall, 81% of patients were aware of hospice, but only 6% seriously considered hospice for themselves at the time of enrollment (Table). 84% were aware of treating their symptoms only, yet only 10% seriously considered that option, and only 7% considered no treatment at all. 69% of patients were aware of other clinical trials, and 29% seriously considered that option for themselves. Of patients, 75% felt they understood the risks and benefits very well and 25% somewhat well. 62% of the patients felt the most useful information to their decision to participate in the trial was whether the agent killed cancer cells; the second most useful piece of information was side effects of the drug (12%). In considering phase I trials, 24% would not participate if the drug caused a temporary mental impairment, while only 10% would not participate if the experimental drug had a 10% chance of death. Regarding pressure, 78% of the patients said they felt moderate or a lot of pressure to participate I in the phase I oncology study because their cancer was growing. Only 7% felt either a moderate or a lot of pressure from the researchers or their families to participate. Conclusion: Patients in phase I trials are aware of alternatives but do not consider them seriously for themselves. Key to their decision-making are not risks of the research agent, but knowing that it can kill cancer cells. Any pressure to participate in the phase I trial comes from their cancer and not from other people. No significant financial relationships to disclose.
Standardised methods of data collection are required
Authors: M. C Shaw
Journal: BMJ (1995)

EDITOR,—John Shanks and colleagues discuss the advantages, for the purpose of needs assessment, of combining knowledge from general practice with that derived from data sources held centrally.1 They suggest that health authorities and family health services authorities may need to wait for a merger to explore the benefits. In East Sussex both authorities have been exploring this for the past two years.

The idea of providing general practitioners with census results for combination with information derived from their own systems …
Comorbidities of the underserved and minority patient with cancer presenting to a public safety-net hospital: A deterrent for clinical trial participation?
Authors: S. N. Wolff, Z. Brifkani, P. Millner, K. Palka, D. Wujcik
Journal: Journal of Clinical Oncology (2010)

1607 Background: Adult cancer patients, especially underserved and minorities, infrequently participate in national clinical trials. Our hospital has an active MBCCOP and U54 clinical trials program caring predominantly for underserved and minority patients including the those of the Department of Correction. We hypothesized that many underserved patients evaluated for national phase II or III cancer clinical trials are ineligible due to advanced disease and/or concomitant comorbidities unrelated to cancer. To better define the comorbidities of our patients we present an ongoing review of the extent of non-cancer-related comorbidities. Methods: We reviewed the charts of 100 consecutive patients presenting for evaluation and cancer treatment at the Nashville General Hospital at Meharry in 2008. The presenting history, physical examination and laboratory data were analyzed. Data were defined as baseline if measured within four weeks of first evaluation. Results: Mean age (range) was 51 (23-91) years and 42% were female. The most common cancer diagnoses were: GI (23.9%); gynecologic (15.6%); breast (12.8%); lung (11.9%) and prostate (9.2%). 87% of patients were ECOG PS 0-1. Conclusions: The results of our study revealed a substantial frequency of co- morbidities per patient that may have precluded trial participation. Comparisons of these presenting parameters to patients presenting at other types of health care facilities such as a tertiary care referral institution and private practices are ongoing. This data supports consideration to review cancer clinical trial eligibility criteria to increase applicability and generalizability to underserved and minority patients. Supported by NIH/NCI 5 U10 CA107612 06 and 5 U54 CA091408 08. Noncancer comorbidity % of patients Tobacco use 66 Using pain meds 55 Hypertension 52 Alcohol use 42 Pulmonary disease 26 Active infections 26 GI disease 24 Psychiatric disorder 23 Diabetes 15 Renal disease 15 Liver dysfunction 14 Heart disease 10 Median # per patient (range) 4 (1-11) No significant financial relationships to disclose.
Influence of residual disease and extreme drug resistance assays on outcome in patients with epithelial ovarian cancer
Authors: A. Karam, J. Wang Chiang, E. Fung, V. Nossov, B. Y. Karlan
Journal: Journal of Clinical Oncology (2009)

5504 Background: Extreme drug resistance (EDR) assays have been used as tools in identifying those agents that are least likely to be of clinical benefit in the treatment of epithelial ovarian cancer (EOC). We sought to examine the effect of obtaining EDR assays on the outcome of patients with EOC in the primary and recurrent setting. Methods: We conducted a retrospective review of demographic, pathologic, EDR assay and outcome data from 377 patients with EOC who had an assay sent at the time of their diagnosis or at recurrence. Univariate followed by multivariate analyses using Cox proportional hazards method were performed to identify and estimate the impact of independent prognostic factors on time to progression (TTP), overall survival (OS) and survival after recurrence (RS). Results: Increasing age was associated with a worse OS and RS (HR = 1.34; 95% CI, 1.14–1.58 and HR = 1.14; 95% CI, 1.00–1.31, for each decade increase in age respectively). Compared with patients with microscopic residual disease, patients who were left with 0.1 to 1.0 cm and &gt;1.0 cm residual disease had an increased risk of recurrence (HR=1.94; 95% CI, 1.33 to 2.84 and HR=3.61; 95% CI; 2.07 to 6.39, respectively) and death (HR = 1.59; 95% CI, 1.03 to 2.45; and HR = 2.14; 95% CI, 1.09 to 4.20, respectively). For patients who recurred, those who did not undergo secondary cytoreductive surgery and patients who were left with &gt;1.0 cm residual had an increased risk of death compared to patients with microscopic residual (HR = 2.13; 95% CI, 1.28 to 3.54; and HR = 2.84; 95% CI, 1.71 to 4.71, respectively). EDR assay results for single agents or combinations did not independently predict patient outcomes. Conclusions: The amount of residual disease continues to be an important prognostic factor, especially when all macroscopic disease is removed both in the primary and recurrent setting. Increasing age is also an independent predictor of OS and RS. EDR assay results do not independently predict or alter the outcomes of patients with EOC who are treated with the current standard of care including optimal cytoreductive surgery followed by platinum and taxane combination chemotherapy in either the primary or recurrent setting. No significant financial relationships to disclose.
Mortality of Radiation Chimeras in Relation to the Number of Transplanted Bone Marrow and Lymph Node Cells&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: O Vos
Journal: JNCI Journal of the National Cancer Institute (1966)

Journal Article Mortality of Radiation Chimeras in Relation to the Number of Transplanted Bone Marrow and Lymph Node Cells Get access O. Vos O. Vos Medical Biological Laboratory of the National Defense Research Organization T.N.O., Rijswijk (Z.H.), The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 36, Issue 3, March 1966, Pages 431–443, https://doi.org/10.1093/jnci/36.3.431 Published: 01 March 1966 Article history Received: 24 May 1965 Published: 01 March 1966
Occupational asthma from sensitization to a chlorine-containing triclosan cleaner
Authors: Gareth Walters, Alastair Robertson, Vicky Moore, Sherwood Burge
Journal: European Respiratory Journal (2014)

We present evidence for respiratory sensitization to the chlorine-releasing antimicrobial compound triclosan, in a nursery nurse with occupational asthma. A 26-year old female was referred to the occupational lung disease clinic with a 7-month history of asthma symptoms progressively worse throughout the working week and better on days away from work. She required treatment with a combination corticosteroid and long-acting beta agonist inhaler. She had experienced previous childhood asthma, mild hay fever and an allergy to peanuts and hazelnuts. Her job required her to care for 30 infants and also to mop the floor daily using trisodium nitrilo-triacetate cleaner (Versatile) and clean tables while wearing nitrile gloves using triclosan-containing cleaner (Antibac). Serial peak flow readings showed evidence of occupational asthma (OASYS score=3.5) and spirometry was normal in clinic (FEV1=3.55L /103%; FVC=4.05/103%) while exposed at work. She underwent specific inhalational challenge to 70% alcohol gel (normal), Versatile cleaner (immediate irritant reaction) and to Antibac cleaner by painting on to cardboard for 30-38 minutes. Antibac caused an immediate asthmatic reaction with a maximum fall from baseline FEV1 (3.48L) of 24%. Non-specific bronchial reactivity and FENO remained normal throughout the challenge. The worker was partially relocated, and Antibac was substituted for an alternative cleaning agent. There is evidence from epidemiological study that triclosan exposure is associated with allergic sensitization to personal care products and cleaners (Bertelsen et al. Allergy 2013;68:84-91); however this is the first reported case of respiratory sensitization to a triclosan-containing cleaner.
Estrogens Suppress a Behavioral Phenotype in Zebrafish Mutants of the Autism Risk Gene, CNTNAP2
Authors: Ellen J. Hoffman, Katherine J. Turner, Joseph M. Fernandez, Daniel Cifuentes, Marcus Ghosh, Sundas Ijaz, Roshan A. Jain, Fumi Kubo, Brent R. Bill, Herwig Baier, Michael Granato, Michael J.F. Barresi, Stephen W. Wilson, Jason Rihel, Matthew W. State, Antonio J. Giraldez
Journal: Neuron (2016)
Leukemia cell DNA content: predictor of late relapse in acute lymphoblastic leukemia.
Authors: G D Hammond
Journal: Journal of Clinical Oncology (1991)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1991.9.8.1332 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2072136 Leukemia cell DNA content: predictor of late relapse in acute lymphoblastic leukemia. G D HammondxG D HammondSearch for articles by this author https://doi.org/10.1200/JCO.1991.9.8.1332 PDF "Leukemia cell DNA content: predictor of late relapse in acute lymphoblastic leukemia.." Journal of Clinical Oncology, 9(8), pp. 1332–1333© 1991 by American Society of Clinical Oncology
Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer.
Authors: M Spielmann, T Dorval, F Turpin, E Antoine, M Jouve, F Maylevin, D Lacombe, J Rouesse, P Pouillart, T Tursz
Journal: Journal of Clinical Oncology (1994)

PURPOSE The study investigated the therapeutic effects of a combination of Navelbine (vinorelbine or 5'noranhydrovinblastine; Pierre Fabre Médicament, Boulogne, France) and doxorubicin in women who had received no prior chemotherapy for locally advanced or metastatic breast cancer. PATIENTS AND METHODS Ninety-seven patients with progressive and assessable advanced or metastatic breast cancer who had received no prior chemotherapy except in an adjuvant setting were entered onto the study. Eighty-nine patients were assessable for toxicity and response by World Health Organization (WHO) criteria; the other eight patients were excluded because they did not meet entry criteria or because of protocol violations. Navelbine was administered at 25 mg/m2 by 30-minute intravenous (IV) infusion on days 1 and 8, and doxorubicin at 50 mg/m2 by slow IV infusion on day 1, with each course repeated at 3-week intervals. Patients were treated for a maximum of 11 cycles or until progression or major toxicity. RESULTS Objective responses were observed in 66 of 89 assessable patients (74%; 95% confidence interval, 63% to 85%). There were nineteen (21%) complete responses (CRs) and 47 (53%) partial responses (PRs). In addition, 20 patients (22.5%) had stable disease and three (3.5%) progressed while on treatment. Responses were observed at all sites of metastatic disease. Forty-one of 58 patients with visceral disease responded (71%) and 25 of 31 with soft tissue and bone disease experienced an objective response (81%). The median duration of response was 12 months (range, 2.4 to 40.5), and the median overall survival was 27.5 months (range, 4 to 46). Neutropenia was dose-limiting, with 36 patients (41%) experiencing grade 3 or 4 toxicity. Of 727 cycles administered, there were 20 admissions (3%) for treatment of febrile neutropenia, involving 14 of 89 patients (16%). Treatment-related cardiotoxicity at grade 2 to 4 was experienced by 10% of patients and necessitated the interruption of treatment in 1.5% of cycles. Other side effects were uncommon or manageable by conventional means. CONCLUSION The encouraging response rates and duration achieved with this combination of Navelbine/doxorubicin under the conditions of this study deserve further randomized comparative trials with standard regimens.
Relationship between gene polymorphism in FGF10 and susceptibility to 220 patients with COPD
Authors: Ping Wang, Yi Liu, Jiating Ren
Journal: European Respiratory Journal (2014)

Objective Fibroblast growth factor 10 (FGF10) signaling pathway is crucial to the reconstruction of lung development and lung epithelial .To investigate the relationship between gene polymorphism and susceptibility in fibroblast growth factor 10 (FGF10 ) to chronic obstructive pulmonary disease (COPD) in Han population of North China. Methods A case–control study of 220 COPD patients and 285 control subject was conducted. Six tagging SNPs in FGF10, including rs10473352, rs16873956, rs2973644, rs1011814, rs10402070, rs723166 and rs723166 were genotyped by RFLP (rs10473352, rs16873956 and rs2973644) and SNaPshot (rs10402070, rs723166 and rs723166) assay. Chi-square test was used to perform the Hardy-Weinberg test. Uncondition logistic of regression model was used to calculate odds ratio (OR) and 95% confidence interval (CI).Age,smoking index, duration of disease,body mass index by t-test. Results The alleles and genotypes of rs2973644 distributed significantly differently in COPD patients and controls (χ2 =6.188,6.021 P< 0.05) The genotypes of rs10473352 distributed significantly differently in COPD patients and controls(χ2 =6.213 P< 0.05). The CC genotype of rs1011814 greatly increased in patients with severer COPD than that in mild COPD. The allele C at rs1011814 was associated with an increased severity of COPD in dominant model analysis (χ2 =6.264 P<0.05; OR: 2.380; 95%CI: 1.193-4.746). Conclusion FGF10 gene SNPsites rs2973644, rs10473352 polymorphism may be associated with susceptibility to COPD in Han population of North China..Thers1011814 SNP may be associated with severity of COPD.